Audrey Greenberg, CBM’s Chief Business Officer has been selected as a 2023 Philadelphia Titan 100 honoree

The Titan 100 program recognizes the top 100 CEOs & C-level executives. They are the area’s most accomplished business leaders in their industry using criteria that includes demonstrating exceptional leadership, vision, and passion.

Collectively the 2023 Philadelphia Titan 100 and their companies employ more than 93,000  individuals and generate over $33 billion dollars in annual revenues. This year’s honorees will be published in a limited-edition Philadelphia Titan 100 book and profiled online. They will be honored at the annual awards ceremony on September 21st, 2023, and will be given the opportunity to interact and connect multiple times throughout the year with their fellow Titans, both locally and nationally.  

The Titan 100 embodies the true diversity of the Philadelphia business landscape. Representing technology, manufacturing, education, healthcare, construction/real estate, staffing, professional services, hospitality, transportation, and the energy sector among many others.

For more information and a complete list of Titans, please click here.

About The Center for Breakthrough Medicines (CBM)

Center for Breakthrough Medicines (CBM) is a purpose-built and patient-driven, cell and gene therapy contract development and manufacturing organization (CDMO) uniquely positioned to enable pharma and biotech companies to develop, test, and manufacture life-saving therapies on a global scale. Ideally located in the heart of Philadelphia’s Cellicon Valley, CBM has assembled the most accomplished cell and gene therapy experts in the world, armed with cutting-edge and innovative technologies, to offer scalable, end-to-end, best-in-class services from pre-clinical through commercial, including process development, plasmid DNA, vector manufacturing, cell banking, cell processing, and a full suite of complementary and standalone testing and analytical capabilities.